Biotechnology
WPI-MANA Team: Biogenic Iron Sulfide Nanoparticles Enable Electron Uptake in Bacteria
TSUKUBA, Japan, Nov. 20, 2020 /PRNewswire/ -- A MANA team has identified the mechanism underlying the synthesis of long, electrically conductive pathways via iron sulfide (FeS) nanoparticles (NPs) in bacteria. This has implications in the development of new ways to inhibit microbial iron corrosio...
2020-11-20 14:00
1077
China Biologic Enters into Definitive Merger Agreement for Going Private Transaction
BEIJING, Nov. 19, 2020 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company inChina, today announced that it has entered into a definitive Agreement and Plan of Merger (the "Merg...
2020-11-19 21:09
8824
WuXi Advanced Therapies Expands Philadelphia Campus with New State-of-The-Art Testing Laboratory
PHILADELPHIA, Nov. 18, 2020 /PRNewswire/ -- WuXi Advanced Therapies Inc. (WuXi ATU) – a business unit of WuXi AppTec offering end-to-end contract services for the cell and gene therapies industry – today announced the completion of a facility expansion that will triple its advanced testing capaci...
2020-11-18 21:00
1519
Samsung Biologics breaks ground on Super Plant, the world's largest and most innovative bio-manufacturing facility
INCHEON, South Korea, Nov. 18, 2020 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS) officially began construction of its Plant 4 in Incheon,South Korea. Dubbed the "Super Plant," the new, multi-story 238,000-square-meter construction will be the world's largest biopharmaceutical manufacturing ...
2020-11-18 20:00
1549
Samsung Biologics announces strategic manufacturing partnership with Lilly to accelerate delivery of COVID-19 antibody treatments
INDIANAPOLIS and INCHEON, South Korea, Nov. 17, 2020 /PRNewswire/ -- Samsung Biologics' partnership with Eli Lilly and Company is expected to greatly accelerate the global supply for Lilly's COVID-19 antibody therapies through a long-term manufacturing agreement, with the ultimate goal of making ...
2020-11-17 20:00
1413
Foresee Pharmaceuticals Enters Exclusive License Agreement with GenSci for the Commercialization of Camcevi(TM) in China
TAIPEI, Nov. 17, 2020 /PRNewswire/ -- Foresee Pharmaceuticals (6576.TWO) ("Foresee") announced today that it has entered into an exclusive license agreement with GenScience Pharmaceuticals ("GenSci") - a wholly-owned subsidiary of Changchun High-Tech Industry (Group) Co., Ltd. (000661.SZ) - for ...
2020-11-17 17:51
1653
PTC Therapeutics Announces Initiation of Phase 2/3 Clinical Trial in Australia to Evaluate PTC299 for the Treatment of COVID-19
– Oral treatment with novel dual-mechanism of action has the potential to address the two critical elements of COVID-19: viral replication and uncontrolled inflammatory response – – Randomized, double-blind, placebo-controlled, Phase 2/3 clinical study with two stages initiated at several sites ...
2020-11-16 05:00
1416
Biortus Announces Round A Financing and Launches Global Cryo-EM Innovation Center
WUXI, China, Nov. 13, 2020 /PRNewswire/ -- Wuxi Biortus Biosciences Co. Ltd. ("Biortus"), a global leader in structural biology service for drug discovery, recently closed round A financing withUS$15 million investment led by Bayland Capital, and the fund will be used to establish a global cryo-E...
2020-11-14 12:40
8515
China Biologic Products to Report Third Quarter 2020 Financial Results
BEIJING, Nov. 13, 2020 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company inChina, today announced that the Company plans to release its third quarter 2020 financial results o...
2020-11-13 21:00
7385
I-Mab Announces Preclinical Data on Differentiated Anti-C5aR Antibody TJ210/MOR210 at SITC 2020
SHANGHAI and GAITHERSBURG, Md., Nov. 11, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced new preclinical data fromin vivo and in vitro studies of...
2020-11-11 21:00
5096
Bioheng Announced Oral Presentation of Its Preliminary Results of CRISPR-Engineered Allogeneic CAR-T for r/r B-ALL Treatment at 2020 ASH Meeting
HANGZHOU and NANJING, China, Nov. 10, 2020 /PRNewswire/ -- Bioheng Biotech Co., Ltd, a clinical-stage biotechnology company focuses on developing novel cellular immunotherapy, today announced that their preliminary data including the pre-clinical development, manufacturing, and investigator initi...
2020-11-10 22:30
1511
I-Mab Reports Phase 1 Clinical Trial Data of Highly Differentiated Anti-CD47 Monoclonal Antibody Lemzoparlimab at the 2020 SITC Annual Meeting
SHANGHAI and GAITHERSBURG, Md., Nov. 9, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced initial results from its U.S. phase 1 clinical trial (NCT...
2020-11-09 21:12
3660
VolitionRx Limited Schedules Third Quarter 2020 Earnings Conference Call and Business Update
AUSTIN, Texas, Nov. 9, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will host a conference call onFriday, November 13, at 8:30 a.m. Eastern time to discuss its financial and operating results for the third quarter 2020, in addition to providing a b...
2020-11-09 21:00
5250
GenScript Receives FDA Emergency Use Authorization for World's First SARS-CoV-2 Neutralizing Antibody Detection Kit
PISCATAWAY, N.J., Nov. 9, 2020 /PRNewswire/ -- GenScript USA Inc., the world's
leading research reagent provider, announced today that the U.S. Food and Drug
Administration (FDA) has grantedEmergency Use Authorization (EUA)
2020-11-09 20:30
3542
TaiGen Partners with GPCR to develop Burixafor & Taigexyn(R)
TAIPEI, Nov. 9, 2020 /PRNewswire/ -- TaiGen Biotechnology Company, Limited ("TaiGen") announced today that they have signed an exclusive agreement with GPCR Therapeutics, Inc. ("GPCR"), a leading Korean biotechnology company, for the continued development of Burixafor worldwide and the commercial...
2020-11-09 18:22
1592
Termination of Bridge Biotherapeutics's Collaboration and License Agreement with Boehringer Ingelheim
SEONGNAM, South Korea, Nov. 9, 2020 /PRNewswire/ -- On November 9, 2020, Bridge Biotherapeutics (288330 KQ) reported to the Korea Stock Exchange that the Company and Boehringer Ingelheim have mutually agreed on the termination of the Collaboration and License Agreement entered into inJuly 2019 to...
2020-11-09 18:07
1369
PolyActiva successfully completes initial clinical trial with Latanoprost FA SR Ocular Implant delivering glaucoma treatment to patients over a six-month period
NEW YORK, Nov. 5, 2020 /PRNewswire/ -- PolyActiva Pty Ltd, a clinical-stage Australian ophthalmology biopharmaceutical company, today announced it has successfully completed its Phase I clinical study for its lead candidate, the Latanoprost FA SR Ocular Implant. The device was well tolerated in ...
2020-11-05 21:00
891
Gracell Biotechnologies Announces Two Oral Presentations at the ASH Annual Meeting and Exposition 2020
SUZHOU and SHANGHAI, China, Nov. 4, 2020 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced two oral presentations at the...
2020-11-05 11:52
1165
Samsung Biologics' Virtual Exhibition Hall earns top industry award for digital creativity and innovation
INCHEON, South Korea, Oct. 4, 2020 /PRNewswire/ -- Samsung Biologics' Virtual Exhibition Hall was recently recognized for its highly interactive digital capabilities and virtual reality (VR) technology to connect with clients around the world. The company's experiential platform won the Best Digi...
2020-11-04 20:00
1583
Great Bay Bio Announces Its First AI-enabled Bioprocessing Platform-Klone 4.0, Reducing Cell Line Development Time and Cost by Up to 80%
HONG KONG, Nov. 2, 2020 /PRNewswire/ -- Klone 4.0 accomplishes both in a manner that could potentially disrupt the bioprocessing industry, firstly by reducing development times by up to 80% as AI eliminates many of the laboratory pain points through GBB's proprietary deep machine learning techniq...
2020-11-02 22:00
1156
Week's Top Stories
Most Reposted
LINKDOOD Breaks Language Barriers, Ushering a New Era for Cross-Border Romance
[Picked up by 326 media titles]
2024-04-29 06:00
Dow showcases circular and innovative materials science solutions and industry collaborations at Chinaplas 2024
[Picked up by 293 media titles]
2024-04-30 10:11
Puyuan Fashion Resort 2024: A Grand Unveiling of Global Trends and Local Heritage
[Picked up by 269 media titles]
2024-04-28 09:39
TAILG Makes Grand Appearance at 2024 Asiabike Jakarta, Aiming to Set the Benchmark in Indonesia
[Picked up by 257 media titles]
2024-05-02 01:21
Chinese new energy industry contributes to global green, low-carbon transition
[Picked up by 251 media titles]
2024-04-30 15:13Most Read
Ferretti's Dazzling Presence at the 2024 Singapore Yachting Festival: Showcasing Evolving Trends in Luxury Yachting
2024-04-28 15:02
2946
Scienjoy Holding Corporation Reports Fiscal Year 2023 Financial Results
2024-04-27 04:30
2943
